Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H1 2017

  • ID: 4315551
  • Report
  • 84 pages
  • Global Markets Direct
1 of 5
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H1 2017

Summary:

According to the recently published report 'Exportin 1 - Pipeline Review, H1 2017'; Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli.

The report 'Exportin 1 - Pipeline Review, H1 2017' outlays comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology and Infectious Disease which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Prostate Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Hematological Tumor, Malignant Mesothelioma, Melanoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Amyotrophic Lateral Sclerosis, B-Cell Leukemia, Bone Sarcoma, Burkitt Lymphoma, Cervical Cancer, Chondrosarcoma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Duchenne Muscular Dystrophy, Endometrial Cancer, Equine Encephalitis, Fallopian Tube Cancer, Follicular Lymphoma, Gastrointestinal Tract Cancer, Hepatitis C, Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus (HPV) Associated Cancer, Influenzavirus A Infections, Leiomyosarcoma, Leukemias, Liposarcoma, Lymphoma, Mantle Cell Lymphoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Multiple Sclerosis, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Respiratory Syncytial Virus (RSV) Infections, Rheumatoid Arthritis, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Synovial Sarcoma, Systemic Lupus Erythematosus, T-Cell Lymphomas, Thymoma (Thymic Epithelial Tumor), Traumatic Brain Injury, Venezuelan Equine Encephalitis and Waldenstrom Macroglobulinemia.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)
  • The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
  1. Introduction
  2. Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Overview
  3. Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Assessment
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Companies Involved in Therapeutics Development
  13. CanBas Co Ltd
  14. Karyopharm Therapeutics Inc
  15. Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Drug Profiles
  16. KPT-251 - Drug Profile
  17. Product Description
  18. Mechanism Of Action
  19. R&D Progress
  20. KPT-276 - Drug Profile
  21. Product Description
  22. Mechanism Of Action
  23. R&D Progress
  24. KPT-350 - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. KPT-8602 - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. selinexor - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. SL-801 - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. verdinexor - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Dormant Products
  45. Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Discontinued Products
  46. Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Product Development Milestones
  47. Featured News & Press Releases
  48. Jun 07, 2017: Karyopharm Doses First Patient in Pivotal Phase 3 BOSTON Study Evaluating Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
  49. May 18, 2017: Karyopharm's Phase 2b SADAL Data Evaluating Selinexor in Diffuse Large B-Cell Lymphoma Selected for Oral Presentation at the 2017 European Hematology Association Annual Meeting
  50. Apr 04, 2017: Karyopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting
  51. Feb 21, 2017: Stemline Therapeutics Provides Update on SL-801
  52. Dec 15, 2016: Karyopharm and Collaborators Awarded Grant for ALS Research
  53. Dec 05, 2016: Karyopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual Meeting
  54. Dec 04, 2016: Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting
  55. Dec 04, 2016: Karyopharm Presents Updated Phase 2b STORM Data at the American Society of Hematology 2016 Annual Meeting
  56. Nov 30, 2016: Karyopharm and the Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought Leaders
  57. Nov 03, 2016: Karyopharm to Present Updated Phase 2b STORM and Phase 1b STOMP Clinical Data at the American Society of Hematology 2016 Annual Meeting
  58. Oct 05, 2016: Karyopharm to Present Updated SIGN Phase 2 Clinical Data at European Society of Medical Oncology 2016 Annual Meeting
  59. Sep 29, 2016: Scientists find lethal vulnerability in treatment-resistant lung cancer
  60. Sep 28, 2016: Karyopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research Publication
  61. Sep 06, 2016: Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma
  62. Aug 30, 2016: Karyopharm to Host Conference Call with Update on Multiple Myeloma Plans
  63. Appendix
  64. Methodology
  65. Coverage
  66. Secondary Research
  67. Primary Research
  68. Expert Panel Validation
  69. Contact Us
  70. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products under Development by Indications, H1 2017 (Contd..1), H1
  5. Number of Products under Development by Indications, H1 2017 (Contd..2), H1
  6. Number of Products under Development by Indications, H1 2017 (Contd..3), H1
  7. Number of Products under Development by Companies, H1
  8. Products under Development by Companies, H1
  9. Products under Development by Companies, H1 2017 (Contd..1), H1
  10. Products under Development by Companies, H1 2017 (Contd..2), H1
  11. Products under Development by Companies, H1 2017 (Contd..3), H1
  12. Number of Products by Stage and Mechanism of Actions, H1
  13. Number of Products by Stage and Route of Administration, H1
  14. Number of Products by Stage and Molecule Type, H1
  15. Pipeline by CanBas Co Ltd, H1
  16. Pipeline by Karyopharm Therapeutics Inc, H1
  17. Dormant Products, H1
  18. Dormant Products, H1 2017 (Contd..1), H1
  19. Discontinued Products, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Routes of Administration, H1
  6. Number of Products by Stage and Routes of Administration, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • CanBas Co Ltd
  • Karyopharm Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll